Watanabe Todd has disclosed the sale of 4,377 shares of Arcutis Biotherapeutics, Inc. The shares were sold for an aggregate market value of approximately $139,466. This transaction is significant as it reflects ongoing activity within the pharmaceutical preparations sector.

Watanabe Todd is associated with Arcutis Biotherapeutics, which operates under the Central Index Key (CIK) 0001787306. The company is classified under the SIC code for pharmaceutical preparations. The recent filing indicates that Todd Watanabe is an officer of Arcutis Biotherapeutics, which is based in Westlake Village, California.

According to the filing, the shares sold were acquired through a restricted stock vesting transaction that took place on November 1, 2026. The filing states, "nothing to report flag on securities sold in past 3 months" indicating no other recent sales.

This sale may affect stakeholders in Arcutis Biotherapeutics, as it provides insight into the trading activities of key company officers. Investors and analysts often monitor such transactions for indications of confidence in the company’s future performance.

The filing does not say what happens next.

Details of the Transaction

The filing indicates that the shares were sold on November 2, 2026, with the sale being executed through Merrill Lynch, a well-known brokerage firm. This transaction involved common shares of Arcutis Biotherapeutics, which had a total of 125,691,961 units outstanding at the time of the sale.

The filing states, "The approximate sale date is 11/02/2026," confirming the timing of this transaction.

Company Background

Arcutis Biotherapeutics, Inc. is incorporated in Delaware and operates under the SEC file number 001-39186. The company's business address is located at 3027 Townsgate Road, Suite 300, Westlake Village, California, 91361, where it conducts its pharmaceutical preparations business.

Additionally, the filing notes that Todd Watanabe was formerly known as Todd Franklin Watanabe, a name change that took effect on January 23, 2020.

Market Context

While the filing provides specific details regarding the transaction, it does not include any information on the broader market conditions or the current performance of Arcutis Biotherapeutics, which could provide further context for the significance of this sale.